| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 67 | 2024 | 498 | 11.280 |
Why?
|
| Influenza, Human | 51 | 2024 | 700 | 8.410 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 17 | 2021 | 61 | 4.530 |
Why?
|
| Antibodies, Viral | 49 | 2024 | 1204 | 3.410 |
Why?
|
| Vaccines, Inactivated | 30 | 2024 | 148 | 3.120 |
Why?
|
| Adjuvants, Immunologic | 20 | 2024 | 392 | 2.190 |
Why?
|
| Immunogenicity, Vaccine | 8 | 2024 | 114 | 1.770 |
Why?
|
| Anthrax Vaccines | 14 | 2019 | 26 | 1.730 |
Why?
|
| Vaccination | 27 | 2024 | 1018 | 1.690 |
Why?
|
| Immunization, Secondary | 17 | 2024 | 113 | 1.630 |
Why?
|
| Hemagglutination Inhibition Tests | 23 | 2024 | 114 | 1.500 |
Why?
|
| Influenza A virus | 12 | 2020 | 152 | 1.390 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 6 | 2020 | 123 | 1.280 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 8 | 2023 | 189 | 1.240 |
Why?
|
| Seasons | 7 | 2023 | 328 | 1.160 |
Why?
|
| Anthrax | 8 | 2019 | 31 | 1.140 |
Why?
|
| Disease Outbreaks | 7 | 2009 | 329 | 1.130 |
Why?
|
| Antibodies, Bacterial | 18 | 2017 | 406 | 1.130 |
Why?
|
| Influenza A Virus, H7N9 Subtype | 4 | 2024 | 30 | 1.110 |
Why?
|
| Immunity, Cellular | 2 | 2020 | 203 | 1.060 |
Why?
|
| Vaccines, Synthetic | 14 | 2011 | 322 | 0.940 |
Why?
|
| Double-Blind Method | 30 | 2023 | 1653 | 0.900 |
Why?
|
| Influenza A Virus, H7N7 Subtype | 2 | 2020 | 11 | 0.810 |
Why?
|
| Young Adult | 29 | 2024 | 9965 | 0.810 |
Why?
|
| Pertussis Vaccine | 8 | 2006 | 25 | 0.790 |
Why?
|
| Adult | 80 | 2024 | 31600 | 0.790 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 8 | 2012 | 62 | 0.770 |
Why?
|
| Aluminum Hydroxide | 5 | 2023 | 39 | 0.740 |
Why?
|
| Whooping Cough | 8 | 2006 | 61 | 0.740 |
Why?
|
| Antigens, Bacterial | 10 | 2016 | 324 | 0.690 |
Why?
|
| Vaccines, Attenuated | 13 | 2019 | 176 | 0.680 |
Why?
|
| Adolescent | 49 | 2020 | 20557 | 0.670 |
Why?
|
| Hemagglutinins | 5 | 2021 | 25 | 0.650 |
Why?
|
| Influenza in Birds | 1 | 2020 | 28 | 0.650 |
Why?
|
| Lipid A | 2 | 2019 | 24 | 0.650 |
Why?
|
| Humans | 123 | 2024 | 132201 | 0.640 |
Why?
|
| Injections, Intramuscular | 15 | 2016 | 196 | 0.640 |
Why?
|
| Influenza B virus | 8 | 2023 | 100 | 0.630 |
Why?
|
| Immunization Schedule | 9 | 2024 | 107 | 0.610 |
Why?
|
| Glucosides | 1 | 2019 | 48 | 0.610 |
Why?
|
| Schistosomiasis | 1 | 2019 | 54 | 0.610 |
Why?
|
| Antibodies, Helminth | 1 | 2019 | 125 | 0.600 |
Why?
|
| Squalene | 6 | 2024 | 25 | 0.570 |
Why?
|
| Respiratory Tract Infections | 3 | 2022 | 291 | 0.560 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2022 | 496 | 0.540 |
Why?
|
| Malaria Vaccines | 3 | 2010 | 24 | 0.530 |
Why?
|
| Female | 68 | 2024 | 70754 | 0.520 |
Why?
|
| Polysaccharides, Bacterial | 2 | 2013 | 67 | 0.510 |
Why?
|
| Orthomyxoviridae | 3 | 2008 | 52 | 0.500 |
Why?
|
| Vaccines | 2 | 2019 | 381 | 0.500 |
Why?
|
| Male | 63 | 2024 | 64979 | 0.480 |
Why?
|
| Polysorbates | 6 | 2024 | 27 | 0.480 |
Why?
|
| Immunoglobulin G | 11 | 2023 | 803 | 0.480 |
Why?
|
| Francisella tularensis | 2 | 2017 | 16 | 0.450 |
Why?
|
| Dose-Response Relationship, Immunologic | 12 | 2016 | 108 | 0.440 |
Why?
|
| Bacterial Vaccines | 2 | 2017 | 103 | 0.430 |
Why?
|
| Bordetella pertussis | 6 | 2006 | 16 | 0.430 |
Why?
|
| Middle Aged | 47 | 2024 | 29007 | 0.430 |
Why?
|
| Antibodies, Neutralizing | 9 | 2024 | 500 | 0.420 |
Why?
|
| Bacillus anthracis | 4 | 2016 | 40 | 0.420 |
Why?
|
| Antigens, Viral | 4 | 2012 | 439 | 0.410 |
Why?
|
| Glucans | 1 | 2013 | 15 | 0.410 |
Why?
|
| Mannans | 1 | 2013 | 15 | 0.410 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 305 | 0.400 |
Why?
|
| Malaria, Falciparum | 2 | 2010 | 70 | 0.360 |
Why?
|
| Zika Virus Infection | 2 | 2024 | 175 | 0.360 |
Why?
|
| Bacterial Toxins | 6 | 2016 | 176 | 0.360 |
Why?
|
| Protozoan Proteins | 2 | 2010 | 134 | 0.350 |
Why?
|
| Hemagglutinins, Viral | 5 | 2009 | 25 | 0.330 |
Why?
|
| Antigens, Protozoan | 1 | 2010 | 79 | 0.320 |
Why?
|
| Clinical Trials as Topic | 7 | 2016 | 1161 | 0.310 |
Why?
|
| Cytokines | 4 | 2020 | 1365 | 0.310 |
Why?
|
| Recombinant Proteins | 4 | 2009 | 1350 | 0.310 |
Why?
|
| Vaccines, DNA | 1 | 2009 | 48 | 0.310 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2013 | 413 | 0.300 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 742 | 0.290 |
Why?
|
| Injections, Intradermal | 4 | 2015 | 31 | 0.290 |
Why?
|
| Neutralization Tests | 11 | 2017 | 237 | 0.280 |
Why?
|
| United States | 13 | 2024 | 11675 | 0.280 |
Why?
|
| Tuberculosis | 1 | 2013 | 556 | 0.260 |
Why?
|
| Prospective Studies | 12 | 2024 | 6569 | 0.260 |
Why?
|
| Smallpox Vaccine | 2 | 2017 | 38 | 0.240 |
Why?
|
| Aged | 23 | 2019 | 21456 | 0.240 |
Why?
|
| alpha-Tocopherol | 4 | 2024 | 36 | 0.240 |
Why?
|
| Healthy Volunteers | 3 | 2024 | 152 | 0.230 |
Why?
|
| Animals | 16 | 2023 | 34842 | 0.230 |
Why?
|
| Plasmodium falciparum | 2 | 2010 | 96 | 0.230 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2016 | 356 | 0.230 |
Why?
|
| Placebos | 5 | 2016 | 235 | 0.230 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2017 | 826 | 0.220 |
Why?
|
| Zika Virus | 2 | 2024 | 151 | 0.220 |
Why?
|
| Injections, Subcutaneous | 6 | 2017 | 126 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 1671 | 0.210 |
Why?
|
| Schistosoma mansoni | 2 | 2023 | 24 | 0.210 |
Why?
|
| Merozoite Surface Protein 1 | 2 | 2002 | 11 | 0.210 |
Why?
|
| Dengue | 1 | 2024 | 122 | 0.210 |
Why?
|
| Pregnancy | 7 | 2024 | 7557 | 0.200 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2002 | 76 | 0.200 |
Why?
|
| Vaccines, Combined | 1 | 2023 | 39 | 0.200 |
Why?
|
| Schistosomiasis mansoni | 1 | 2023 | 24 | 0.200 |
Why?
|
| HIV Infections | 3 | 2012 | 2050 | 0.200 |
Why?
|
| Antibody Formation | 5 | 2013 | 274 | 0.190 |
Why?
|
| Azithromycin | 1 | 2022 | 43 | 0.190 |
Why?
|
| Viral Vaccines | 3 | 2011 | 343 | 0.190 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2021 | 13 | 0.180 |
Why?
|
| Tetanus Toxoid | 2 | 2013 | 50 | 0.180 |
Why?
|
| Metagenome | 2 | 2012 | 146 | 0.180 |
Why?
|
| Interferon-gamma | 3 | 2015 | 539 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2015 | 277 | 0.170 |
Why?
|
| Birds | 1 | 2020 | 86 | 0.160 |
Why?
|
| Herpes Zoster | 2 | 2013 | 26 | 0.160 |
Why?
|
| Age Factors | 8 | 2015 | 2920 | 0.160 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 2 | 2011 | 12 | 0.160 |
Why?
|
| Immunoglobulin A | 4 | 2009 | 218 | 0.150 |
Why?
|
| Learning Curve | 1 | 2019 | 57 | 0.150 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 1999 | 130 | 0.150 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2024 | 554 | 0.150 |
Why?
|
| Nasal Mucosa | 3 | 2007 | 68 | 0.150 |
Why?
|
| Virus Shedding | 2 | 2003 | 82 | 0.150 |
Why?
|
| Europe | 2 | 2010 | 373 | 0.150 |
Why?
|
| Child | 12 | 2022 | 25783 | 0.140 |
Why?
|
| Binding Sites, Antibody | 2 | 2009 | 99 | 0.140 |
Why?
|
| Antigens, Helminth | 1 | 2019 | 188 | 0.140 |
Why?
|
| Propensity Score | 1 | 2019 | 255 | 0.140 |
Why?
|
| Tularemia | 1 | 2017 | 13 | 0.140 |
Why?
|
| Drug Combinations | 4 | 2024 | 280 | 0.130 |
Why?
|
| Vaccinia virus | 1 | 2017 | 49 | 0.130 |
Why?
|
| Neuraminidase | 3 | 2012 | 39 | 0.130 |
Why?
|
| Peptide Fragments | 2 | 2002 | 800 | 0.130 |
Why?
|
| Hepatitis Delta Virus | 1 | 1996 | 6 | 0.120 |
Why?
|
| Drug Carriers | 1 | 2017 | 119 | 0.120 |
Why?
|
| Pneumococcal Vaccines | 1 | 2017 | 172 | 0.120 |
Why?
|
| Herpesvirus 4, Human | 3 | 2003 | 673 | 0.120 |
Why?
|
| Child, Preschool | 6 | 2024 | 14735 | 0.120 |
Why?
|
| Granzymes | 1 | 2015 | 48 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2022 | 5173 | 0.120 |
Why?
|
| Antibodies, Protozoan | 2 | 2010 | 95 | 0.120 |
Why?
|
| Pneumococcal Infections | 1 | 2017 | 277 | 0.120 |
Why?
|
| Pain | 2 | 1995 | 462 | 0.120 |
Why?
|
| Streptococcus pneumoniae | 1 | 2017 | 381 | 0.120 |
Why?
|
| Time Factors | 9 | 2015 | 6452 | 0.110 |
Why?
|
| Cough | 1 | 1995 | 96 | 0.110 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2012 | 235 | 0.110 |
Why?
|
| Cross Reactions | 3 | 2015 | 189 | 0.110 |
Why?
|
| Research Personnel | 2 | 2013 | 136 | 0.110 |
Why?
|
| Antibody Affinity | 3 | 2009 | 41 | 0.110 |
Why?
|
| Antibody Specificity | 4 | 2008 | 201 | 0.110 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 1 | 1994 | 3 | 0.110 |
Why?
|
| Typhoid Fever | 1 | 1994 | 18 | 0.110 |
Why?
|
| Guatemala | 2 | 2024 | 64 | 0.100 |
Why?
|
| Administration, Intranasal | 4 | 2009 | 140 | 0.100 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2013 | 11 | 0.100 |
Why?
|
| JC Virus | 2 | 2003 | 29 | 0.100 |
Why?
|
| Acetylmuramyl-Alanyl-Isoglutamine | 1 | 1993 | 1 | 0.100 |
Why?
|
| Phosphatidylethanolamines | 1 | 1993 | 22 | 0.100 |
Why?
|
| Emulsions | 2 | 2009 | 70 | 0.100 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2013 | 35 | 0.100 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2013 | 84 | 0.100 |
Why?
|
| Rabbits | 2 | 2009 | 673 | 0.100 |
Why?
|
| Sex Factors | 2 | 2014 | 1354 | 0.100 |
Why?
|
| Elephants | 1 | 2013 | 44 | 0.090 |
Why?
|
| Infant | 5 | 2024 | 13048 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 229 | 0.090 |
Why?
|
| Circadian Rhythm | 1 | 1995 | 316 | 0.090 |
Why?
|
| Cold Temperature | 4 | 2000 | 83 | 0.090 |
Why?
|
| Ethics, Research | 1 | 2012 | 55 | 0.090 |
Why?
|
| Mouth | 1 | 2012 | 67 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2013 | 1444 | 0.090 |
Why?
|
| Specimen Handling | 1 | 2012 | 151 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 543 | 0.090 |
Why?
|
| Progesterone | 1 | 2014 | 451 | 0.090 |
Why?
|
| Erythema Infectiosum | 1 | 2011 | 8 | 0.090 |
Why?
|
| Parvovirus B19, Human | 1 | 2011 | 31 | 0.090 |
Why?
|
| Metagenomics | 1 | 2012 | 106 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2013 | 1499 | 0.090 |
Why?
|
| Bacterial Proteins | 1 | 2016 | 930 | 0.090 |
Why?
|
| Immunoglobulin M | 2 | 2009 | 216 | 0.090 |
Why?
|
| Vagina | 1 | 2012 | 205 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 540 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 749 | 0.090 |
Why?
|
| Aluminum Compounds | 1 | 2010 | 17 | 0.080 |
Why?
|
| Hospitalization | 1 | 2019 | 1902 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2014 | 1699 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2013 | 494 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2003 | 291 | 0.080 |
Why?
|
| Human Experimentation | 1 | 2010 | 35 | 0.080 |
Why?
|
| Australia | 1 | 2010 | 185 | 0.080 |
Why?
|
| Gastrointestinal Tract | 1 | 2012 | 232 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 1285 | 0.080 |
Why?
|
| Exanthema | 1 | 2011 | 74 | 0.080 |
Why?
|
| Phosphates | 1 | 2010 | 114 | 0.080 |
Why?
|
| HIV-1 | 2 | 2012 | 484 | 0.080 |
Why?
|
| DNA, Viral | 4 | 2003 | 492 | 0.080 |
Why?
|
| Skin | 1 | 2012 | 527 | 0.080 |
Why?
|
| New York | 1 | 2009 | 72 | 0.080 |
Why?
|
| Orthomyxoviridae Infections | 1 | 1990 | 62 | 0.080 |
Why?
|
| Macaca fascicularis | 1 | 2009 | 88 | 0.080 |
Why?
|
| Vaccines, Subunit | 1 | 2009 | 70 | 0.080 |
Why?
|
| Antitoxins | 1 | 2009 | 7 | 0.080 |
Why?
|
| ISCOMs | 1 | 2009 | 3 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 153 | 0.080 |
Why?
|
| Vero Cells | 1 | 2009 | 113 | 0.080 |
Why?
|
| Surface-Active Agents | 1 | 2009 | 30 | 0.070 |
Why?
|
| Interferon Type I | 1 | 2009 | 114 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 312 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2022 | 13028 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2014 | 7123 | 0.070 |
Why?
|
| Immunization | 3 | 2013 | 312 | 0.070 |
Why?
|
| Liposomes | 1 | 2009 | 203 | 0.070 |
Why?
|
| Texas | 4 | 2009 | 3632 | 0.070 |
Why?
|
| Microbiota | 1 | 2013 | 434 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2013 | 554 | 0.070 |
Why?
|
| Virus Activation | 2 | 2005 | 86 | 0.060 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2006 | 37 | 0.060 |
Why?
|
| Research | 1 | 2008 | 266 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2017 | 1250 | 0.060 |
Why?
|
| Drug Approval | 1 | 2005 | 46 | 0.060 |
Why?
|
| Chickenpox Vaccine | 1 | 2005 | 14 | 0.060 |
Why?
|
| Herpesvirus 3, Human | 1 | 2005 | 30 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2003 | 270 | 0.060 |
Why?
|
| Neuralgia | 1 | 2005 | 50 | 0.060 |
Why?
|
| Viral Load | 2 | 2003 | 408 | 0.060 |
Why?
|
| Safety | 3 | 2007 | 216 | 0.050 |
Why?
|
| Outpatients | 1 | 2006 | 275 | 0.050 |
Why?
|
| Neutrophils | 2 | 2004 | 360 | 0.050 |
Why?
|
| Dengue Virus | 1 | 2024 | 132 | 0.050 |
Why?
|
| Streptococcus agalactiae | 1 | 2004 | 103 | 0.050 |
Why?
|
| Viral Matrix Proteins | 1 | 2003 | 110 | 0.050 |
Why?
|
| Brazil | 1 | 2023 | 140 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2003 | 146 | 0.050 |
Why?
|
| BK Virus | 1 | 2003 | 60 | 0.050 |
Why?
|
| Rural Population | 1 | 2024 | 243 | 0.050 |
Why?
|
| Polyomavirus Infections | 1 | 2003 | 91 | 0.050 |
Why?
|
| Protozoan Vaccines | 1 | 2023 | 96 | 0.050 |
Why?
|
| Tumor Virus Infections | 1 | 2003 | 140 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 4 | 2009 | 1036 | 0.050 |
Why?
|
| Quality of Life | 1 | 2012 | 2161 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2003 | 262 | 0.050 |
Why?
|
| Microcephaly | 1 | 2024 | 354 | 0.050 |
Why?
|
| Blood Bactericidal Activity | 1 | 2000 | 17 | 0.040 |
Why?
|
| Virulence Factors, Bordetella | 1 | 2000 | 23 | 0.040 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2019 | 11 | 0.040 |
Why?
|
| Emergency Responders | 1 | 2019 | 18 | 0.040 |
Why?
|
| Toxoids | 1 | 1999 | 7 | 0.040 |
Why?
|
| Viral Proteins | 3 | 2007 | 357 | 0.040 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2019 | 53 | 0.040 |
Why?
|
| Skin Tests | 1 | 1999 | 80 | 0.040 |
Why?
|
| Molecular Sequence Data | 4 | 2007 | 3771 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2019 | 151 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 743 | 0.040 |
Why?
|
| Cricetulus | 2 | 2009 | 93 | 0.040 |
Why?
|
| CHO Cells | 2 | 2009 | 158 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 94 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 134 | 0.040 |
Why?
|
| Cricetinae | 2 | 2009 | 381 | 0.040 |
Why?
|
| Agglutination Tests | 1 | 2017 | 8 | 0.030 |
Why?
|
| Seroconversion | 1 | 2017 | 15 | 0.030 |
Why?
|
| Protein Folding | 2 | 2009 | 223 | 0.030 |
Why?
|
| Serogroup | 1 | 2017 | 63 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1999 | 686 | 0.030 |
Why?
|
| Equivalence Trials as Topic | 1 | 2017 | 24 | 0.030 |
Why?
|
| Viral Plaque Assay | 1 | 2017 | 42 | 0.030 |
Why?
|
| Phagocytes | 1 | 2016 | 24 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 1997 | 80 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 2553 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 69 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 89 | 0.030 |
Why?
|
| Mice | 3 | 2023 | 18504 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2008 | 764 | 0.030 |
Why?
|
| Pleura | 1 | 1995 | 28 | 0.030 |
Why?
|
| Hemagglutination, Viral | 1 | 2015 | 10 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 3 | 2003 | 1554 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2015 | 52 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 2016 | 811 | 0.030 |
Why?
|
| New Jersey | 1 | 1995 | 25 | 0.030 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 1994 | 22 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2016 | 826 | 0.030 |
Why?
|
| Immunity, Mucosal | 2 | 2009 | 94 | 0.030 |
Why?
|
| Freeze Drying | 1 | 1994 | 15 | 0.030 |
Why?
|
| Vaccines, Acellular | 2 | 2006 | 5 | 0.030 |
Why?
|
| Antibodies | 1 | 1995 | 366 | 0.030 |
Why?
|
| Rabies Vaccines | 1 | 2013 | 11 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2016 | 1120 | 0.030 |
Why?
|
| Erythema | 1 | 1993 | 29 | 0.020 |
Why?
|
| Dizziness | 1 | 1993 | 27 | 0.020 |
Why?
|
| Endotoxins | 1 | 1993 | 48 | 0.020 |
Why?
|
| Nausea | 1 | 1993 | 84 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2024 | 8548 | 0.020 |
Why?
|
| Saliva | 2 | 2003 | 133 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2012 | 135 | 0.020 |
Why?
|
| Research Subjects | 1 | 2012 | 54 | 0.020 |
Why?
|
| Fatigue | 1 | 1993 | 201 | 0.020 |
Why?
|
| Health Surveys | 1 | 2012 | 260 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2016 | 1049 | 0.020 |
Why?
|
| Phagocytosis | 2 | 2004 | 191 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2007 | 2669 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2012 | 425 | 0.020 |
Why?
|
| Capsid Proteins | 1 | 2011 | 196 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1444 | 0.020 |
Why?
|
| Virus Replication | 1 | 1994 | 636 | 0.020 |
Why?
|
| Fever | 1 | 1993 | 310 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2012 | 200 | 0.020 |
Why?
|
| Cholera Toxin | 1 | 2009 | 51 | 0.020 |
Why?
|
| Informed Consent | 1 | 2012 | 346 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2013 | 1033 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2009 | 152 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1841 | 0.020 |
Why?
|
| Nucleoproteins | 1 | 1989 | 20 | 0.020 |
Why?
|
| Random Allocation | 1 | 1990 | 431 | 0.020 |
Why?
|
| Base Sequence | 2 | 2003 | 2900 | 0.020 |
Why?
|
| Thimerosal | 1 | 2008 | 3 | 0.020 |
Why?
|
| Serologic Tests | 1 | 2008 | 130 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2008 | 242 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 1990 | 272 | 0.020 |
Why?
|
| Periodicity | 1 | 1988 | 50 | 0.020 |
Why?
|
| Epitopes | 1 | 2009 | 436 | 0.020 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2007 | 14 | 0.020 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2007 | 20 | 0.020 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2007 | 24 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2007 | 50 | 0.020 |
Why?
|
| Complementarity Determining Regions | 1 | 2007 | 26 | 0.020 |
Why?
|
| Incidence | 2 | 2005 | 3377 | 0.020 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2007 | 65 | 0.020 |
Why?
|
| Prevalence | 2 | 2004 | 2663 | 0.020 |
Why?
|
| Genotype | 2 | 2003 | 2702 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2009 | 213 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 1986 | 99 | 0.020 |
Why?
|
| Hepatitis A Vaccines | 1 | 2005 | 10 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 2007 | 441 | 0.020 |
Why?
|
| Glycoproteins | 2 | 2005 | 376 | 0.010 |
Why?
|
| Nursing Homes | 1 | 1986 | 97 | 0.010 |
Why?
|
| Respirovirus | 1 | 1984 | 4 | 0.010 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 1984 | 12 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 2004 | 144 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 2005 | 199 | 0.010 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2003 | 18 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2005 | 285 | 0.010 |
Why?
|
| Urine | 1 | 2003 | 91 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2009 | 3414 | 0.010 |
Why?
|
| Lung | 1 | 1990 | 1556 | 0.010 |
Why?
|
| Gambia | 1 | 2002 | 26 | 0.010 |
Why?
|
| Kenya | 1 | 2002 | 58 | 0.010 |
Why?
|
| Endemic Diseases | 1 | 2002 | 59 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2002 | 171 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2002 | 188 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2002 | 159 | 0.010 |
Why?
|
| Adenylyl Cyclases | 1 | 2000 | 67 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 2000 | 59 | 0.010 |
Why?
|
| Viral Envelope Proteins | 2 | 1996 | 155 | 0.010 |
Why?
|
| Adhesins, Bacterial | 1 | 2000 | 76 | 0.010 |
Why?
|
| Aging | 1 | 2007 | 1251 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1997 | 17391 | 0.010 |
Why?
|
| Russia | 1 | 1996 | 37 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1995 | 60 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 5410 | 0.010 |
Why?
|
| Acclimatization | 1 | 1995 | 24 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2004 | 3760 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1995 | 1008 | 0.010 |
Why?
|
| Maximal Midexpiratory Flow Rate | 1 | 1990 | 3 | 0.010 |
Why?
|
| Vital Capacity | 1 | 1990 | 86 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 1990 | 173 | 0.000 |
Why?
|
| Complement Fixation Tests | 1 | 1989 | 29 | 0.000 |
Why?
|
| Nucleocapsid Proteins | 1 | 1989 | 6 | 0.000 |
Why?
|
| Viral Core Proteins | 1 | 1989 | 23 | 0.000 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1989 | 275 | 0.000 |
Why?
|
| Immunoenzyme Techniques | 1 | 1989 | 249 | 0.000 |
Why?
|
| Acute Disease | 1 | 1991 | 1163 | 0.000 |
Why?
|
| Blotting, Western | 1 | 1989 | 1080 | 0.000 |
Why?
|
| HN Protein | 1 | 1984 | 18 | 0.000 |
Why?
|
| Paramyxoviridae Infections | 1 | 1984 | 49 | 0.000 |
Why?
|
| Viral Fusion Proteins | 1 | 1984 | 76 | 0.000 |
Why?
|
| Asthma | 1 | 1990 | 773 | 0.000 |
Why?
|